Pfizer Inc. $PFE Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. lessened its stake in Pfizer Inc. (NYSE:PFE) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,094,953 shares of the biopharmaceutical company’s stock after selling 43,723 shares during the period. D.A. Davidson & CO. owned 0.05% of Pfizer worth $77,064,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of PFE. Horizon Financial Services LLC boosted its stake in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares in the last quarter. YANKCOM Partnership acquired a new position in Pfizer in the fourth quarter valued at $28,000. Grey Fox Wealth Advisors LLC acquired a new position in Pfizer in the third quarter valued at $29,000. Darwin Wealth Management LLC acquired a new position in Pfizer in the second quarter valued at $32,000. Finally, True Wealth Design LLC boosted its stake in Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 974 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research note on Monday, March 2nd. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 target price on shares of Pfizer in a research note on Monday, March 9th. TD Cowen reiterated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.48.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Board declared a $0.43 Q2 dividend (payable June 12; ex-div May 8), reinforcing Pfizer’s long track record of income (350th consecutive quarterly dividend) and supporting demand from income-minded investors. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: Seagen acquisition appears to be contributing to growth and a stronger oncology franchise (Antibody‑Drug Conjugates), supporting medium-term revenue upside as Pfizer expands cancer capabilities. Pfizer Inc. (PFE): One of the Best Safe Stocks to Invest in for Beginners
• Positive Sentiment: GLP‑1 obesity program momentum — Phase 2b monthly GLP‑1 data and plans for a large clinical program provide optionality beyond legacy drugs and could open a new growth engine if later‑stage trials succeed. Pfizer’s Monthly GLP-1 Push Tests Balance Between Obesity Growth And Dividends
• Positive Sentiment: Multiple early‑stage pipeline advances (completion of a China Phase 1 for a heart‑failure candidate, new gastric‑emptying study for an obesity asset, new Phase 1 cancer and liver studies) add cadence and long‑term upside to the pipeline. Pfizer Advances Early-Stage Heart Failure Candidate With Completion Of Chinese Phase 1 Study
• Neutral Sentiment: Pfizer released results from its 2026 shareholder meeting — largely procedural items that don’t materially change near‑term fundamentals. Pfizer Unveils 2026 Shareholder Meeting Results
• Neutral Sentiment: Bristol Myers and Pfizer will make Eliquis available through Mark Cuban’s Cost Plus pharmacy starting April 27 — improves patient access but raises questions about pricing/volume tradeoffs; watch margin impact. Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban’s online pharmacy
• Neutral Sentiment: Broader industry news — competitors (e.g., Eli Lilly, Novo Nordisk) continue to shape the obesity/GLP‑1 landscape; this is both competitive risk and market validation for Pfizer’s obesity push. Eli Lilly’s new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims
• Negative Sentiment: Pfizer ended a Phase 1 cancer trial, trimming part of its oncology pipeline — a reminder that not all program investments convert to later‑stage value and a near‑term negative headline. Pfizer Ends Early-Stage Cancer Trial, Trimming Its Oncology Pipeline
• Negative Sentiment: Analyst skepticism persists (Barclays remains negative; consensus leans to “hold”), which can cap upside until clearer revenue/cost trajectories emerge. Barclays Remains a Sell on Pfizer (PFE)

Pfizer Price Performance

Shares of PFE opened at $27.01 on Monday. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75. The company has a market capitalization of $153.56 billion, a price-to-earnings ratio of 19.86 and a beta of 0.43. The firm has a 50-day simple moving average of $27.23 and a 200-day simple moving average of $26.06. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.63 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.4%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is currently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.